Search Results - "Lyon, A.R"

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Haanen, J., Obeid, M., Spain, L., Carbonnel, F., Wang, Y., Robert, C., Lyon, A.R., Wick, W., Kostine, M., Peters, S., Jordan, K., Larkin, J.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing immunotherapy-related toxicity.•The guideline covers assessment, diagnosis and…”
Get full text

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations by Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A.R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M.G., Orecchia, R., de Azambuja, E., Zamorano, J.L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C.M., Dent, S., Jordan, K.

“…Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are…”
Get full text

Peri-operative cardiac arrest with ST elevation secondary to gelofusin anaphylaxis — Kounis syndrome in the anaesthetic room by Shah, G, Scadding, G, Nguyen-Lu, N, Wigmore, T, Chenzbraun, A, Wechalekar, K, Sharma, R, Lyon, A.R

Get full text

The year in cardiology : heart failure The year in cardiology 2019 by Lyon, Alexander R., McMurray, John J.V., McDonagh, Theresa, Cleland, John G.F.

“…The past year has brought many new concepts and an abundance of new data on the nature, management, and outcome of heart failure. The pace of change is…”
Get full text

MicroRNA-1202 Is a Candidate Biomarker To Assist Selection of Patients for Therapy With a Left Ventricular Assist Device by Morley-Smith, A.C, Mills, A, Jacobs, S, Meyns, B, Rega, F, Simon, A.R, Pepper, J.R, Lyon, A.R, Thum, T

Get full text

The broad spectrum of cardiovascular adverse events related to immune check point inhibitors by Andres, M.S, Baksi, J, Khattar, R, Rosen, S.D, Lyon, A.R

“…Abstract Background Immunotherapy is one of the latest and most exciting developments in cancer treatment. Immune checkpoint inhibitors (ICI) have shown to…”
Get full text

Radiation Oncology Opinions and Practice on Cardiotoxicity in Lung Cancer: A Cross-sectional Study by the International Cardio-oncology Society by Walls, G.M., Mitchell, J.D., Lyon, A.R., Harbinson, M., Hanna, G.G.

“…Symptomatic radiation cardiotoxicity affects up to 30% patients with lung cancer and several heart substructure doses are associated with reduced overall…”
Get full text

What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist? by Andres, M.S., Pan, J., Lyon, A.R.

“…Cardio-oncology is an emerging subspecialty arising from the need for multidisciplinary collaboration to address the increasing prominence of cardiovascular…”
Get full text

Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer by Reed, N., Glen, H., Gerrard, G., Good, J., Lei, M., Lyon, A.R., Strachan, M., Wadsley, J., Newbold, K.

“…Lenvatinib is an oral multi-kinase inhibitor approved for the treatment of adults with progressive, locally advanced or metastatic, differentiated thyroid…”
Get full text

P6119Cancer and myocardial dysfunction: observations from myocardial strain imaging in a dedicated cardio-oncology clinic by Venneri, L., Danylenko, O., Calicchio, F., Manivarmane, R., Tadic, M., Baksi, J., Rosen, S.D., Senior, R., Lyon, A.R., Khattar, R.S.

Get full text

245Carvedilol vs. metoprolol tartrate on mortality in patients with heart failure with a reduced ejection fraction and atrial fibrillation or sinus rhythm: a post-hoc analysis of COMET by Mareev, Y., Ramparsad, N., McConnachie, A., Olsson, L., Lyon, A.R., Di Lenarda, A., Komajda, M., Torp-Pedersen, C., Metra, M., Swedberg, K., Cleland, J.G.

Get full text

Myocardial tissue engineering: a review by Jawad, H., Ali, N. N., Lyon, A.R., Chen, Q. Z., Harding, S. E., Boccaccini, A. R.

“…Myocardial tissue engineering, a concept that intends to overcome the obstacles to prolonging patients' life after myocardial infarction, is continuously…”
Get full text

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment by Lee, G A, Aktaa, S, Baker, E, Gale, C P, Yaseen, Israa F, Gulati, G, Asteggiano, R, Szmit, S, Cohen-Solal, A, Abdin, A, Jurczak, W, Garrido Lopez, P, Sverdlov, A L, Tocchetti, C G, Barac, A, Parrini, I, Zamorano, P, Iakobishvili, Z, Pudil, R, Badimon, L, Kirby, A M, Blaes, A H, Farmakis, D, Curigliano, G, Stephens, R, Lyon, A R, Lopez-Fernandez, T

“…Abstract Aims To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity…”
Get full text

A phase Ib and randomised phase II trial of pazopanib with or without fosbretabulin in advanced recurrent ovarian cancer by Morgan, R.D., Jayson, G.C., Banerjee, S., Clamp, A.R., Lyon, A.R., Ryder, W.D., Hutson, R., Mescallado, N., Orbegoso Aguilar, C., Taylor, S., Tugwood, J., Hall, M., Dive, C., Rustin, G.J.S.

Get full text

Allied Professionals7Screening for eligibility for subcutaneous icd implant in adults with congenital heart disease: how many patients are eligible?8Identifying the outcome of patients in a multispeciality nurse led rapid access blackout clinic undergoing implantable loop recorders for unexplained syncope9Implant of medtronic linq in an outpatient setting10Does time from diagnosis of atrial fibrillation to ablation effect success of catheter ablation?11Detection and management of atrial fibrilla by Cunningham, S., Hall, A., Jackson, A.J., Jarrett-Smith, L.J.S., Rees, P.A., Brennan, C., Saeed, Y., Ng, F.S., Kirkwood, G.J., Orini, M., Lambiase, P.D., Srinivasan, N.T., Walker, N.L., Wright, G.A., Goodwin, J., Reilly, J., Connelly, D.T., Mudd, P.J., Wilson, C., Rice, A.F., Iglesias, A., Taggart, S., James, S., Thornley, A.R., Turley, A.J., Linker, N.J., Rashid-Fadel, T., Bond, R.C., Rosengarten, J., Thomas, G., Butcher, C.B., Lysitsas, D.L., Wong, T.W., Markides, V.M., Jones, D.G.J., Hussain, W.H., Gilmore, M.A., Barry, J., Patel, K.H., Lowe, M.D., Segal, O.R., Temple, I., Borbas, Z., Atkinson, A., Yanni, J., Boyett, M., Garratt, C., Dobrzynski, H., Roney, C.H., Debney, M.T., Eichhorn, C., Nachiappan, A., Qureshi, N.A., Chowdhury, R.A., Kanagaratnam, P., Lyon, A.R., Peters, N.S., Lawless, M., Pearman, C., Radcliffe, E., Caldwell, J., Trafford, A.W., Taggart, P, Hanson, B, Hayward, M., Lambiase, PD, Hanson, B., Smith, A., Zhang, H., Taggart, P., Simon, R.B., Providencia, R., Babu, G., Vyas, S., Khan, F., Chow, T.

Get full text

Moderated Posters 251Gap junction uncoupling during ischaemia activates normally quiescent purkinje-myocardial junctions resulting in accelerated and more complex activation patterns52The role of gαi2 signalling in cardiac electrophysiology53Midline atrial tachycardia: mapping and differentiation54A multicentre experience of percutaneous left atrial appendage occlusion using different technologies in the united kingdom55Opportunistic screening for atrial fibrillation during flu clinics56Primary by Ng, F.S., Lane, J.D., Nisbet, A.M., Betts, T. R., Arathoon, N., Hayward, C., Opel, A., Abozguia, K., Behradfar, E., Debney, M.T., Nygren, A., Hartley, A., Lyon, A.R., Efimov, I.R., Vigmond, E., Peters, N.S., Montaigne, D., Tinker, A., Walters, T., Wong, M.C.G., Morton, J.B., Sparks, P., Kistler, P., Kalman, J., Leo, M., Panikker, S., Kanagaratnam, P., Koa-Wing, M., Davies, D.W., Hildick-Smith, D., Wynne, D. G., Ormerod, O., Segal, O. R., Chow, A. W., Todd, D., Cabrera Gomes, S., Kirkwood, G. J., Fox, D., Pepper, C., Foran, J., Wong, T., Patel, H., Morley-Smith, A., Patel, K., Lyon, A., Ahsan, S., Akhtar, M.A., Hadjivassilev, S., Ang, R., Finlay, M., Dhinoja, M., Earley, M., Schilling, R., Hunter, R., Sporton, S., Cutler, M., Johnson, J., Rowan, S., Lewis, W., Costantini, O., Natale, A., Ziv, O.

Get full text